Practical experience with empagliflozin in the light of new possibilities: case reports
Authors:
Iveta Marková 1; Lenka Godál 2; Eva Horská 3; Zbynek Schroner 4,5
Authors‘ workplace:
MUDr. Iveta Marková, s. r. o., Nitra
1; Adiamax s. ro., Pezinok
2; Diabetologická ambulancia, Martin
3; SchronerMED, s. r. o, Košice
4; Klinika geriatrie a ošetrovateľstva LF UPJŠ a VŠOÚG sv. Lukáša v Košiciach n. o.
5
Published in:
Diab Obez 2022; 22(44): 103-107
Category:
Labels
Diabetology ObesitologyArticle was published in
Diabetes a obezita
2022 Issue 44
Most read in this issue
- Finerenone – a new option to reduce the risk of progression of renal and cardiovascular damage in patients with chronic kidney disease and type 2 diabetes mellitus
- MAFLD screening in real practice in Slovakia: the SIRIUS study
- New therapeutic indications for SGLT2 inhibitors
- Effect of intensive lifestyle modification in patients with obesity (even extreme obesity) on cardiometabolic parameters